Deciphera Pharmaceuticals, Inc. (DCPH) Stock

About Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapies to significantly improve outcomes for cancer patients. Their core strategy involves tackling the mechanisms of drug resistance that often limit the effectiveness and longevity of current cancer treatments, serving markets both domestically and internationally. The company's flagship product, QINLOCK, is employed in the treatment of gastrointestinal stromal tumors (GIST) and is additionally undergoing a Phase 3 clinical trial (INTRIGUE study) for second-line GIST. Deciphera's pipeline also includes vimseltinib, a potent, orally available, and highly selective switch-control kinase inhibitor targeting colony stimulating factor 1 receptor (CSF1R) for tenosynovial giant cell tumor (TGCT). Furthermore, they are advancing DCC-3116, currently in preclinical development, which targets RAS/RAF mutant cancers. Established in 2003, Deciphera Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Deciphera Pharmaceuticals, Inc. is headquartered in US.

Deciphera Pharmaceuticals, Inc. (DCPH) stock trades at $25.59 with a market capitalization of $2.21B. The stock is valued at a price-to-earnings (P/E) ratio of -11.17, price-to-book of 6.20, price-to-sales of 13.55. Over the past 52 weeks the stock has ranged between $9.90 and $25.61, and currently trades at its 52-week high.

On profitability, Deciphera Pharmaceuticals, Inc. generates a return on equity (ROE) of -56.29%, return on capital employed of -56.51%, an operating margin of -129.14%, a net profit margin of -119.34%.

Official website: www.deciphera.com